GlaxoSmithKline plc (LON:GSK) has been assigned a GBX 1,450 ($19.13) price objective by equities research analysts at Morgan Stanley in a research note issued on Monday. The brokerage currently has a “sell” rating on the stock. Morgan Stanley’s price objective would suggest a potential upside of 6.27% from the company’s previous close.
Other equities analysts have also issued research reports about the company. Jefferies Group LLC reissued a “buy” rating and issued a GBX 1,900 ($25.07) target price on shares of GlaxoSmithKline plc in a research report on Thursday, July 13th. Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($25.07) target price on GlaxoSmithKline plc and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Bryan, Garnier & Co boosted their target price on GlaxoSmithKline plc from GBX 1,750 ($23.09) to GBX 1,790 ($23.62) and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,885 ($24.87) price target on shares of GlaxoSmithKline plc in a research report on Wednesday, July 26th. Finally, Investec reaffirmed a “buy” rating and set a GBX 1,800 ($23.75) price target on shares of GlaxoSmithKline plc in a research report on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of GBX 1,612.25 ($21.28).
Shares of GlaxoSmithKline plc (GSK) opened at GBX 1,364.47 ($18.01) on Monday.
GlaxoSmithKline plc (LON:GSK) last issued its earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share for the quarter, topping the Zacks’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). GlaxoSmithKline plc had a negative return on equity of 57.19% and a negative net margin of 1.17%. The business had revenue of GBX 784.30 billion during the quarter.
WARNING: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/06/glaxosmithkline-plc-gsk-pt-set-at-gbx-1450-by-morgan-stanley.html.
In other news, insider Simon Dingemans purchased 1,076 shares of the business’s stock in a transaction dated Thursday, October 12th. The shares were purchased at an average price of GBX 1,527 ($20.15) per share, for a total transaction of £16,430.52 ($21,681.87). Also, insider Urs Rohner purchased 473 shares of the business’s stock in a transaction dated Wednesday, October 25th. The shares were purchased at an average price of GBX 1,518 ($20.03) per share, for a total transaction of £7,180.14 ($9,474.98). In the last quarter, insiders acquired 1,574 shares of company stock worth $2,398,888.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.